No Data
RBC Capital Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $12
RBC Capital analyst Brian Abrahams maintains $Applied Therapeutics(APLT.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 51.1
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)
Express News | RBC Capital Reiterates Outperform on Applied Therapeutics, Maintains $12 Price Target
Applied Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/17/2024 117.79% RBC Capital $12 → $12 Reiterates Outperform → Outperform 04/11/2024 117.79% RBC
CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 40 points on Tuesday.Shares of CrossFirst Bankshares, Inc. (NASDAQ:CFB) fell sharply in today's pre-market trading
Express News | Applied Therapeutics Was Added To The Russell 3000 Index, Effective After The U.S. Market Closed On June 28, 2024, As Part Of The 2024 Russell Indexes Annual Reconstitution